US20020006644A1 - Method for preparing an R- or S-form of alpha-substituted heterocyclic carboxylic acid and a counter enantiomeric form of alpha-substituted heterocyclic carboxylic acid ester thereto using enzyme - Google Patents
Method for preparing an R- or S-form of alpha-substituted heterocyclic carboxylic acid and a counter enantiomeric form of alpha-substituted heterocyclic carboxylic acid ester thereto using enzyme Download PDFInfo
- Publication number
- US20020006644A1 US20020006644A1 US09/870,209 US87020901A US2002006644A1 US 20020006644 A1 US20020006644 A1 US 20020006644A1 US 87020901 A US87020901 A US 87020901A US 2002006644 A1 US2002006644 A1 US 2002006644A1
- Authority
- US
- United States
- Prior art keywords
- carboxylic acid
- enzyme
- substituted heterocyclic
- thfa
- heterocyclic carboxylic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 COC(=O)C1*CCC1 Chemical compound COC(=O)C1*CCC1 0.000 description 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C7/00—Purification; Separation; Use of additives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Definitions
- the present invention relates to a method for preparing an R- or S-form ⁇ -substituted heterocyclic carboxylic acid (hereinafter referred to as “ ⁇ -HCCA”) and a counter enantiomeric form of ⁇ -HCCA ester. More particularly, the present invention pertains to a method for preparing R- or S-form ⁇ -HCCA and S- or R-form ⁇ -HCCA ester, respectively using an enzyme catalyst with enantioselectivity from a racemate of ⁇ -HCCA ester obtained by reacting a racemic ⁇ -HCCA and alcohol.
- THFA tetrahydro-2-furoic acid
- R-(+)-THFA is used as a side chain intermediate for the synthesis of penem type antibiotics
- S-( ⁇ )-THFA is useful as a chiral intermediate for organic synthesis.
- THFA is different in use from R form to S form.
- additional processes are required to separate THFA into enantiomers thereof: R and S forms.
- Japanese Pat. Laid-Open Publication No. 89-216983 discloses the use of a chiral amine (1-(4-halogenophenyl)ethylamine) as a resolving agent, in which diastereomer salts are prepared from R,S-THFA and optically resolved. This method is also economically unfavorable owing to the high price of the chiral amine. Additionally, only low production yields can be obtained because the amount of R,S-THFA to be added in the early reaction is limited to as low as 4 mmol. Furthermore, the chiral THFA finally obtained is poor in enantiomeric excess value.
- Japanese Pat. Laid-Open Publication. No. 97-71576 refers to a method of synthesizing R- or S-THFA by treating R- or S-THFA salts with hydrogen halide, which is different from optical resolving methods.
- racemates could be optically resolved using enzyme catalysts, such as esterases, lipases, and proteases, to enantioselectively hydrolyze one of the two enantiomers present.
- enzyme catalysts such as esterases, lipases, and proteases
- U.S. Pat. No. 5,928,933 discloses an enzyme with an enantiomeric excess value of 95% as a result of extensive experiments for reaction specificity of 44 enzymes, including proteases, lipases and esterases.
- the enzyme catalyst is very useful for the separation of enantiomeric racemates, but because the selectivity for enantiomers and the optical purity of products may vary depending on the choice of enzyme and the chemical structures of substrates, intensive efforts are required to find combinations of enzymes suitable for substrates. Especially, nowhere is found a method for optical resolution of ⁇ -HCCA using an enzyme.
- R 1 is selected from the group consisting of substituted or unsubstituted alkyl or alkenyl containing 1 to 6 carbon atoms, benzyl, cycloalkyl containing 3 to 6 carbon atoms, substituted or unsubstituted arylalkyl, and substituted or unsubstituted heteroarylalkyl, X represents O, S or N, and n is an integer of 1 to 3;
- the present invention is characterized by the enantioselective hydrolysis of esters of racemic ⁇ -HCCA by an enzyme to produce a certain enantiomeric form of ⁇ -HCCA and a counter enantiomeric form of the esters of ⁇ -HCCA, at once.
- the separation of the hydrolyzed ⁇ -HCCA and the remaining esters of ⁇ -HCCA can be achieved by extracting with an organic solvent.
- ⁇ -HCCA is reacted with an alcohol at an equivalent amount to produce an ⁇ -HCCA ester, which is then enantioselectively hydrolyzed at a constant temperature and pH in an aqueous solution in the presence of an enzyme with enantioselectivity.
- the reaction produces an R- or S-form ⁇ -HCCA, along with the ester of ⁇ -HCCA which has an enantiomeric form counter to that of the hydrolyzed ⁇ -HCCA.
- addition of an organic solvent extracts the ester of ⁇ -HCCA thereinto, leaving the ⁇ -HCCA in the aqueous phase only.
- the ⁇ -HCCA remaining in the aqueous solution may be increased in purity through a purification process using, for example, a column, or may be reused as a starting material in the present invention.
- the S- or R-form of ⁇ -HCCA ester obtained can be hydrolyzed to an S- or R-form of ⁇ -HCCA with a high enantiomeric excess value (>99%). Additionally, the S- or R-form of ⁇ -HCCA ester may be reduced to a chiral alcohol which is useful as an intermediate for the synthesis of various medicines.
- the enantiomeric ⁇ -HCCA ester is hydrolyzed at a constant pH and temperature in an aqueous solution in the presence of an enzyme that shows no enantioselectivity and non-specifically hydrolyzes ⁇ -HCCA ester.
- the aqueous layer is controlled to pH 2-3 with hydrochloric acid and extracted several times with an organic solvent to yield an S- or R-form of ⁇ -HCCA.
- the obtained S- or R-form of ⁇ -HCCA ester is dissolved in an organic solvent and subjected to hydrogenation at a constant temperature under a predetermined partial hydrogen pressure to produce an S- or R-form of ⁇ -HCCA with a high optical purity (>99%).
- THFA which belongs to an ⁇ -HCCA
- alcohol is reacted with alcohol at an equivalent amount to give a THFA ester adduct which is then subjected to optical resolution in the presence of an enantioselectively hydrolyzing enzyme to afford an R- or S-form of THFA while leaving a counter enantiomeric form of the THFA ester, which is extracted with an organic solvent.
- this enantiomeric THFA ester can be returned to an enantiomeric form of THFA with a high optical purity (>99%).
- all materials falling within the scope of ⁇ -HCCA for example, proline and tetrahydrothiopen-2-carboxylic acid can be optically resolved in accordance with the present invention.
- Useful in the present invention are linear or branched alcohols containing 1-6 carbon atoms, aromatic alcohols, cycloalkyl alcohols containing 3-6 carbon atoms, substituted or unsubstituted arylalkyl alcohols, and substituted or unsubstituted heteroarylalkyl alcohols.
- Preferred are linear alcohols containing 4 or more carbon atoms or aromatic alcohols, when consideration is taken of reaction time and optical purity.
- the enzyme is preferably selected from the group consisting of lipases, proteases, and esterases, all of which are derived from microorganisms or animals. Depending on enzymes, the conformation of the ⁇ -HCCA hydrolyzed is determined.
- Such an enantioselective enzyme when used, may be in a form of a powder or an aqueous solution.
- the enzyme is preferably used in an amount of 0.1 to 100 parts by weight based on 100 parts by weight of the ⁇ -HCCA ester. For example, if the enzyme amount is less than 0.1 part by weight, the hydrolysis may require excessive time to complete. On the other hand, an enzyme amount exceeding 100 parts by weight increases the production cost.
- the enzymatic reaction is optimally carried out at 0-60° C. and pH 4-12.
- the organic solvent to extract the remaining enantiomeric ⁇ -HCCA ester it is preferably selected from the group consisting of ethyl acetate, dichloromethane, chloroform, carbon tetrachloride, toluene and mixtures thereof.
- a palladium catalyst is preferably used in an amount of 0.1 to 30% by weight and more preferably in an amount of 0.5 to 10% by weight. For example, an amount less than 0.1% by weight is insufficient to perform the hydrogenation. On the other hand, an amount larger than 30% by weight has negative influence on the production cost.
- the catalytic hydrogenation of the enantiomeric ⁇ -HCCA ester is preferably carried out at a hydrogen partial pressure of 1 to 10 Bars and more preferably at a hydrogen partial pressure of 1 to 5 Bars.
- the hydrogenation when being carried out at a hydrogen partial pressure less than 1 bar, is significantly deteriorated in efficiency.
- a hydrogen partial pressure larger than 10 Bars results in a lot of side products.
- Other conditions are set at 1 to 20 hours and preferably at 1 to 8 hours for reaction time and at 0 to 70° C. and preferably at 20 to 40° C. for reaction temperature.
- THFA 0.1 mole of THFA was reacted with 0.1 mole of butyl alcohol at 120° C. for 4 hours in 0.15 mole of toluene in the presence of 1 ⁇ 10 ⁇ 4 mole of p-toluenesulfonic acid to produce THFA butyl ester.
- THFA benzyl ester was prepared in a manner similar to 10 that of Example 1, except that benzyl alcohol was used.
- Racemic THFA ester was enantioselectively hydrolyzed by an enzyme and an organic solvent was added to the enzyme reaction to separate the R- or S-form of the product THFA from the corresponding S- or R-form of the substrate remaining unhydrolyzed as follows.
- Example 4 The same procedure as in Example 4 was conducted, except that the concentration of R, S-THFA butyl ester was fixed at 8% by weight while varying the ratio of enzyme:substrate, reaction temperature, and pH. Results are given in Table 4, below. TABLE 4 Example Enz.:Su Rxn Rxn Optical No. b Time (hr) Temp.
- S-THFA butyl ester was prepared in a manner similar to that of Example 14, except that the hydrolysis was carried out at 20° C. for 26 hours with 15% by weight of R, S-THFA butyl ester in 200 ml of a 50 mM phosphate buffer (pH 9.0) and 100 ml of ethyl acetate was added for substrate separation, and its optical purity was measured to be 99.8% in enantiomeric excess.
- Example 23 The procedure of Example 23 was carried out using different enzymes, and the results are given in Table 6, below. TABLE 6 Example Rxn No. Enzyme Time (hr) ee % (S-THFA) 24 Aspergillus oryzae lipase 16 100 25 Fongipase 16 100 26 Pseudomonas sp. Lipase 16 100 (immobilized) 27 Pseudomonas sp. Lipase 16 100 28 Candida sp. Lipase 1.5 100 29 Candida antarctica , 1 100 fraction B Lipase 30 Novo IM Lipase 5 100 31 L62 lipase 2.5 100 32 Porcine liver Esterase 0.15 100
- a benzyl ester racemate was prepared in the same manner as in Example 3. To 200 ml of a 50 mM phosphate buffer (pH 9.0) were added 12% by weight of the prepared R, S-THFA butyl ester and 1% by weight of Bacillus licheniformis protease and the resulting reaction was incubated at 20° C. for 4.5 hours with maintenance of pH 9.0. After completion of the hydrolysis, the reaction was analyzed as in Example 1. The remainder of the reaction was added with 100 ml of ethyl acetate and mixed well, after which 16 g of S-THFA butyl ester was obtained in the same manner as in Example 14 and identified to be 99.1% in enantiomeric excess.
- ⁇ -HCCA and ester thereof can be prepared as enantiomeric compounds with high optical purity at high yields in accordance with the present invention. Additionally, the present invention is economically favorable because such chiral compounds can be produced at low cost.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Water Supply & Treatment (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
- 1. Field of the Invention
- The present invention relates to a method for preparing an R- or S-form α-substituted heterocyclic carboxylic acid (hereinafter referred to as “α-HCCA”) and a counter enantiomeric form of α-HCCA ester. More particularly, the present invention pertains to a method for preparing R- or S-form α-HCCA and S- or R-form α-HCCA ester, respectively using an enzyme catalyst with enantioselectivity from a racemate of α-HCCA ester obtained by reacting a racemic α-HCCA and alcohol.
- 2. Description of the Prior Art
- Divided into optical isomers, R- and S-form, tetrahydro-2-furoic acid (hereinafter referred to as “THFA”), a kind of α-HCCA, is an important chiral building block which has various applications in chemistry. Of the optical isomers, R-(+)-THFA is used as a side chain intermediate for the synthesis of penem type antibiotics while S-(−)-THFA is useful as a chiral intermediate for organic synthesis. Thus, THFA is different in use from R form to S form. However, because THFA is obtained in the form of racemate when chemically synthesized, additional processes are required to separate THFA into enantiomers thereof: R and S forms.
- Optical resolution has been usually used to divide racemic THFA into R- and S-forms thereof. In 1983, Belanger successfully separated THFA racemate into enantiomers thereof by use of brucine and ephedrine as resolving agents (Can. J. Chem., 61, 1383 (1983)). However, the resolving agents are not economical because of their being very expensive. Another problem with this process is low in enantiomeric excess value.
- Japanese Pat. Laid-Open Publication No. 89-216983 discloses the use of a chiral amine (1-(4-halogenophenyl)ethylamine) as a resolving agent, in which diastereomer salts are prepared from R,S-THFA and optically resolved. This method is also economically unfavorable owing to the high price of the chiral amine. Additionally, only low production yields can be obtained because the amount of R,S-THFA to be added in the early reaction is limited to as low as 4 mmol. Furthermore, the chiral THFA finally obtained is poor in enantiomeric excess value.
- Japanese Pat. Laid-Open Publication. No. 97-71576 refers to a method of synthesizing R- or S-THFA by treating R- or S-THFA salts with hydrogen halide, which is different from optical resolving methods.
- It has been well known for some time that racemates could be optically resolved using enzyme catalysts, such as esterases, lipases, and proteases, to enantioselectively hydrolyze one of the two enantiomers present. For example, U.S. Pat. No. 5,928,933 discloses an enzyme with an enantiomeric excess value of 95% as a result of extensive experiments for reaction specificity of 44 enzymes, including proteases, lipases and esterases. The enzyme catalyst is very useful for the separation of enantiomeric racemates, but because the selectivity for enantiomers and the optical purity of products may vary depending on the choice of enzyme and the chemical structures of substrates, intensive efforts are required to find combinations of enzymes suitable for substrates. Especially, nowhere is found a method for optical resolution of α-HCCA using an enzyme.
- Leading to the present invention, the intensive and through research on the optical resolution of α-HCCA, conducted by the present inventors aiming to develop an optically highly pure α-HCCA and a counter enantiomeric form of α-HCCA ester thereto by an economical procedure, resulted in the finding that some of microorganism- or animal-derived hydrolyzing enzymes may enantioselectively hydrolyze the ester functionality of particular optical isomers of α-HCCA esters at high efficiency.
- Therefore, it is an object of the present invention to overcome the above problems encountered in prior arts and to provide a method for preparing a highly pure R- or S-form α-HCCA and a counter enantiomeric form of α-HCCA ester thereto using an enzyme, which is economically favorable.
- Based on the present invention the above object could be accomplished by providing a method for preparing an R- or S-form α-HCCA and a counter enantiomeric form of α-HCCA ester thereto, comprising the steps of:
-
- wherein, R1 is selected from the group consisting of substituted or unsubstituted alkyl or alkenyl containing 1 to 6 carbon atoms, benzyl, cycloalkyl containing 3 to 6 carbon atoms, substituted or unsubstituted arylalkyl, and substituted or unsubstituted heteroarylalkyl, X represents O, S or N, and n is an integer of 1 to 3;
- optically resolving the racemate of the formula 1 by use of an enzyme with enantioselectivity to hydrolyze either R-form or S-form of the racemate, thereby producing a pure R-form or S-form of α-HCCA and a counter enantiomeric form of α-HCCA ester thereto, said enzyme existing as a powder or an aqueous solution; and
- extracting the unhydrolyzed α-HCCA ester with an organic solvent.
- The present invention is characterized by the enantioselective hydrolysis of esters of racemic α-HCCA by an enzyme to produce a certain enantiomeric form of α-HCCA and a counter enantiomeric form of the esters of α-HCCA, at once. The separation of the hydrolyzed α-HCCA and the remaining esters of α-HCCA can be achieved by extracting with an organic solvent.
- In detail, α-HCCA is reacted with an alcohol at an equivalent amount to produce an α-HCCA ester, which is then enantioselectively hydrolyzed at a constant temperature and pH in an aqueous solution in the presence of an enzyme with enantioselectivity. As a result, the reaction produces an R- or S-form α-HCCA, along with the ester of α-HCCA which has an enantiomeric form counter to that of the hydrolyzed α-HCCA. After completion of the enantioselective hydrolysis, addition of an organic solvent extracts the ester of α-HCCA thereinto, leaving the α-HCCA in the aqueous phase only. Removal of the organic phase results in acquisition of an optically pure S- or R-form of α-HCCA ester. Poor in optical purity, the α-HCCA remaining in the aqueous solution may be increased in purity through a purification process using, for example, a column, or may be reused as a starting material in the present invention.
- Using a non-enantioselective enzyme or a palladium catalyst, the S- or R-form of α-HCCA ester obtained can be hydrolyzed to an S- or R-form of α-HCCA with a high enantiomeric excess value (>99%). Additionally, the S- or R-form of α-HCCA ester may be reduced to a chiral alcohol which is useful as an intermediate for the synthesis of various medicines.
- For instance, the enantiomeric α-HCCA ester is hydrolyzed at a constant pH and temperature in an aqueous solution in the presence of an enzyme that shows no enantioselectivity and non-specifically hydrolyzes α-HCCA ester. After completion of the enzymatic hydrolysis, the aqueous layer is controlled to pH 2-3 with hydrochloric acid and extracted several times with an organic solvent to yield an S- or R-form of α-HCCA. In the case of an palladium catalyst (Pd/C), the obtained S- or R-form of α-HCCA ester is dissolved in an organic solvent and subjected to hydrogenation at a constant temperature under a predetermined partial hydrogen pressure to produce an S- or R-form of α-HCCA with a high optical purity (>99%).
- In accordance with a preferred embodiment of the present invention, THFA, which belongs to an α-HCCA, is reacted with alcohol at an equivalent amount to give a THFA ester adduct which is then subjected to optical resolution in the presence of an enantioselectively hydrolyzing enzyme to afford an R- or S-form of THFA while leaving a counter enantiomeric form of the THFA ester, which is extracted with an organic solvent. Using a non-enantioselective enzyme or a palladium catalyst, this enantiomeric THFA ester can be returned to an enantiomeric form of THFA with a high optical purity (>99%). Aside from THFA, all materials falling within the scope of α-HCCA, for example, proline and tetrahydrothiopen-2-carboxylic acid can be optically resolved in accordance with the present invention.
- Useful in the present invention are linear or branched alcohols containing 1-6 carbon atoms, aromatic alcohols, cycloalkyl alcohols containing 3-6 carbon atoms, substituted or unsubstituted arylalkyl alcohols, and substituted or unsubstituted heteroarylalkyl alcohols. Preferred are linear alcohols containing 4 or more carbon atoms or aromatic alcohols, when consideration is taken of reaction time and optical purity.
- For use in the enantioselective hydrolysis of α-HCCA ester, the enzyme is preferably selected from the group consisting of lipases, proteases, and esterases, all of which are derived from microorganisms or animals. Depending on enzymes, the conformation of the α-HCCA hydrolyzed is determined. Such an enantioselective enzyme, when used, may be in a form of a powder or an aqueous solution. The enzyme is preferably used in an amount of 0.1 to 100 parts by weight based on 100 parts by weight of the α-HCCA ester. For example, if the enzyme amount is less than 0.1 part by weight, the hydrolysis may require excessive time to complete. On the other hand, an enzyme amount exceeding 100 parts by weight increases the production cost.
- The enzymatic reaction is optimally carried out at 0-60° C. and pH 4-12. As for the organic solvent to extract the remaining enantiomeric α-HCCA ester, it is preferably selected from the group consisting of ethyl acetate, dichloromethane, chloroform, carbon tetrachloride, toluene and mixtures thereof.
- Turning now to the reduction of the prepared enantiomeric α-HCCA ester to a corresponding conformation of α-HCCA, a palladium catalyst is preferably used in an amount of 0.1 to 30% by weight and more preferably in an amount of 0.5 to 10% by weight. For example, an amount less than 0.1% by weight is insufficient to perform the hydrogenation. On the other hand, an amount larger than 30% by weight has negative influence on the production cost. At this time, the catalytic hydrogenation of the enantiomeric α-HCCA ester is preferably carried out at a hydrogen partial pressure of 1 to 10 Bars and more preferably at a hydrogen partial pressure of 1 to 5 Bars. For example, the hydrogenation, when being carried out at a hydrogen partial pressure less than 1 bar, is significantly deteriorated in efficiency. On the other hand, a hydrogen partial pressure larger than 10 Bars results in a lot of side products. Other conditions are set at 1 to 20 hours and preferably at 1 to 8 hours for reaction time and at 0 to 70° C. and preferably at 20 to 40° C. for reaction temperature.
- A better understanding of the present invention may be obtained in light of the following examples which are set forth to illustrate, but are not to be construed to limit the present invention.
- After being well mixed, 0.1 mole of THFA and 0.3 mole of ethyl alcohol were reacted at 70° C. for 1 hour in the presence of 0.15 mole of thionyl chloride to produce THFA ethyl ester.
- To 500 μl of a 50 mM phosphate buffer (pH 7.0), THFA ethyl ester and a hydrolyzing enzyme were added at amounts of 1% and 0.1%, respectively and the resulting reaction was incubated at 30° C. for 30 hours. After completion of the hydrolysis, 50 μl of the reaction was well mixed with an equal volume of 1 N HCl and added with 200 μl of ethyl acetate to extract the remaining substrate. The extract was analyzed by gas chromatography (GC) on a HP-5 column at a temperature range from 80 to 200° C. and by chiral gas chromatography (GC) on a β-dextrin GC column at a temperature range from 110 to 200° C.
- Analysis results are summarized in Table 1, below. As seen in Table 1, the remaining THFA ethyl ester existed as either an R-form, an S-form or a racemate, depending on the enantioselectivity of the enzymes. Therefore, it is confirmed that different enantiomers of THFA ethyl ester can be prepared according to the choice of enzyme.
TABLE 1 Optical Chiral Form Enzyme Purity (ee%)1 (THFA Ethyl Kind Source THFA-C2 THFA (Ester) Note Protease Papain Unreacted Bacillus subtilis 27.7% 51.2% S Aspergillus oryzae 30.1% 22.3% S Aspergillus saitoi Unreacted Rhizopus. sp Bacillus licheniformis 26% 13.2% S Unreacted Bacillus 0% amyloliquefaciens Lipase Candida cylindracea 88% 12.3% Aspergillus oryzae 15.4% 5.6% R Fongipase 12.2% 9.3% R Pseudomonas sp. 35.3% 5.7% S (immobilized) Pseudomonas sp. 3.1% 0.2% R Candida sp. 21.5% 2.5% R Procine pancreatic 93.1% 19.8% S Candida antartica, fraction B Novo IM lipase 6.2% 2.5% R Candida rugosa 0% Rhizomucor miehei 13.5% 1.1% R K80 lipase 7.6% 8.2% S L1 lipase Unreacted L62 lipase 16.9% 10.5% S Esterase Procine liver 0% Unreacted 1 - 0.1 mole of THFA was reacted with 0.1 mole of butyl alcohol at 120° C. for 4 hours in 0.15 mole of toluene in the presence of 1×10−4 mole of p-toluenesulfonic acid to produce THFA butyl ester.
- To 500 μl of a 50 mM phosphate buffer (pH 7.0), THFA ethyl ester and a hydrolyzing enzyme were added at amounts of 1% and 0.1%, respectively and the resulting reaction was incubated at 30° C. for 16 hours. After completion of the hydrolysis, the substrate was extracted and analyzed in the same manner as in Example 1.
- Analysis results are summarized in Table 2, below. As apparent from data of Table 2, the remaining α-HCCA ethyl ester existed as either an R-form, an S-form or a racemate, depending on the enantioselectivity of the enzymes. Therefore, it is confirmed that different enantiomers of THFA ethyl ester can be prepared according to the choice of enzyme.
TABLE 2 Optical Chiral Form Enzyme Purity (ee%)1 (THFA Butyl Kind Source THFA-C4 THFA Ester) Note Protease Papain Unreacted Bacillus subtilis 16.8% 37.8% S Aspergillus niger 100% 40.5% R Aspergillus oryzae 100% 24.6% S Aspergillus saitoi 5.6% 27.8% R Weakly reacted Rhizopus. sp Unreacted Bacillus licheniformis 100% 29.8% S Bacillus Unreacted amyloliquefaciens Lipase Candida cylindracea 88% 12.3% R Aspergillus oryzae 79.3% 0.6% R Fongipase 76.15% 2.7% R Pseudomonas 35.3% 5.7% S sp. (immobilized) Pseudomonas sp. 19.1% 3.7% S Candida sp. 65.8% 14.1% R Porcine pancreatic 35.7% 20.3% S Candida antarctica, 16.1% 11.3% R fraction B Novo IM lipase 100% 2.96% R Candida rugosa 81% 6% R Rhizomucor miehei Unreacted K80 lipase 51.4% 11% S L1 lipase 47.1% 16.3% R L62 lipase 81.5% 8.4% S Esterase Porcine liver 42.2% 25.3% R 1 - THFA benzyl ester was prepared in a manner similar to 10 that of Example 1, except that benzyl alcohol was used.
- To 500 μl of a 50 mM phosphate buffer (pH 7.0), THFA benzyl ester and a hydrolyzing enzyme were added at amounts of 1% and 0.1%, respectively and the resulting reaction was incubated at 30° C. for 16 hours. After completion of the hydrolysis, the substrate was extracted and analyzed in the same manner as in Example 1.
- Analysis results are summarized in Table 3, below. As apparent from data of Table 3, the remaining α-HCCA benzyl ester existed as either an R-form, an S-form or a racemate, depending on the enantioselectivity of the enzymes. Therefore, it is confirmed that different enantiomers of THFA ethyl ester can be prepared according to the choice of enzyme.
TABLE 3 Optical Chiral Form Enzyme Purity (ee%)1 (THFA-Benzyl Kind Source THFA-Bz THFA Ester) Note Protease Papain Unreacted Bacillus subtilis 94.7% 31.8% S Aspergillus oryzae 98.3% 26.5% S Aspergillus saitoi 22.2% 19.9% S Rhizopus.sp 39.4% 44.1% S Bacillus licheniformis 91.5% 29.1% S Bacillus 83.6% 36% S amyloliquefaciens Lipase Candida cylindracea 0.7% 5.8% — Aspergillus oryzae 18.1% 22% R Fongipase 0% Pseudomonas 13.1% 21.9% S sp. (immobilized) Pseudomonas sp. 1.8% 9.5% S Candida sp. 0% Porcine pancreatic 0% Candida antartica, 35% 10.7% S fraction B Novo IM lipase 78.3% 3.9% R Candida rugosa 0% Rhizomucor miehei 0% K80 lipase 92.1% 20.4% S L1 lipase 40% 6% R L62 lipase 0% Esterase Porcine liver 0% 1 - Racemic THFA ester was enantioselectively hydrolyzed by an enzyme and an organic solvent was added to the enzyme reaction to separate the R- or S-form of the product THFA from the corresponding S- or R-form of the substrate remaining unhydrolyzed as follows.
- To 1 liter of a 50 mM phosphate buffer (pH 7.0), R, S-THFA butyl ester andBacillus licheniformis protease were added at amounts of 2% and 1%, respectively and the resulting reaction was incubated at 30° C. for 4 hours under a condition of pH 7. After completion of the hydrolysis, the substrate was extracted and analyzed in the same manner as in Example 1.
- The remainder of the reaction was added with 500 ml of ethyl acetate and mixed well, followed by phase separation to recover the organic layer. The aqueous layer was extracted one more time with 500 ml of ethyl acetate and the ethyl acetate layers obtained were pooled. This pooled organic layer was dehydrated over 5 g of sodium sulfate. Vacuum distillation removed the ethyl acetate, leaving 9.6 g of S-THFA butyl ester which was measured to be 99.4% in enantiomeric excess. The THFA remaining in the aqueous phase was identified to be an R-form with 70% enantiomeric excess.
- The same procedure as in Example 4 was conducted, except that the concentration of R, S-THFA butyl ester was fixed at 8% by weight while varying the ratio of enzyme:substrate, reaction temperature, and pH. Results are given in Table 4, below.
TABLE 4 Example Enz.:Su Rxn Rxn Optical No. b Time (hr) Temp. (° C.) Purity (ee %) pH 5 1:2 5 50 100 inconstant 6 1:2 2 50 98.6 7 7 1:4 3.5 50 98.4 7 8 1:8 7.5 50 98.9 7 9 1:4 4 50 98.6 9 10 1:8 4 50 98.5 9 11 1:8 4 30 98.7 9 12 1:12 8.5 30 98.8 9 13 1:16 11 30 97.4 9 - To 400 ml of a 50 mM phosphate buffer (pH 9.0) were added 12% by weight of R, S-THFA butyl ester and 1% by weight ofBacillus licheniformis protease and the resulting reaction was incubated at 30° C. for 10.5 hours with maintenance of pH 9.0. After completion of the hydrolysis, the substrate was extracted and analyzed in the same manner as in Example 1.
- Using 200 ml of ethyl acetate, 21 g of S-THFA butyl ester was obtained in the same manner as in Example 4, and analyzed to be 99.3% in enantiomeric excess. The THFA remaining in the aqueous phase was identified to be an R-form with 60% enantiomeric excess.
- 12 g of S-THFA butyl ester was prepared in a manner similar to that of Example 14, except that 200 ml of a 50 mM phosphate buffer (pH 9.0) was used at 20° C. for the hydrolysis and 100 ml of ethyl acetate was added for substrate separation, and its optical purity was measured to be 99.3% enantiomeric excess.
- 21 g of S-THFA butyl ester was prepared in a manner similar to that of Example 14, except that the hydrolysis was carried out at 10° C. for 19 hours, and its optical purity was measured to be 99.1% in enantiomeric excess.
- 25.7 g of S-THFA butyl ester was prepared in a manner similar to that of Example 14, except that the hydrolysis was carried out at 20° C. for 26 hours with 15% by weight of R, S-THFA butyl ester in 200 ml of a 50 mM phosphate buffer (pH 9.0) and 100 ml of ethyl acetate was added for substrate separation, and its optical purity was measured to be 99.8% in enantiomeric excess.
- S-THFA butyl ester was prepared under the same conditions as in Example 17 while varying concentrations of R, S-THFA butyl ester and the ratio of enzyme to substrate according to the instructions of Table 5, below. Analysis results are also given in Table 5.
TABLE 5 Sub. Enz.:Su Rxn Yield Example No. Conc. b Time (hr) (%) ee % 18 15% 1:12 21 25.5 100 19 30% 1:12 24 30 99 20 30% 1:15 26 33.7 99.2 21 40% 1:15 28 46.4 99.1 22 50% 1:12 30 50 99.9 - In the presence ofCandida antarctica, fraction B lipase, which was demonstrated to non-enantioselectively hydrolyze R, S-THFA butyl ester in Example 2, S-THFA butyl ester was hydrolyzed to S-THFA without using strong acid and strong base nor producing isomers.
- To 300 ml of a 50 mM phosphate buffer (pH 7.0) were added 1% by weight of S-THFA butyl ester and 0.1% by weight ofCandida antarctica, fraction B lipase and the resulting reaction was incubated at 30° C. for 1 hour. After completion of the hydrolysis, the substrate was extracted and analyzed in the same manner as in Example 1.
- GC analysis confirmed the hydrolysis of all S-THFA butyl ester to THFA which was found to be 99.8% in enantiomeric excess as measured by chiral GC.
- The procedure of Example 23 was carried out using different enzymes, and the results are given in Table 6, below.
TABLE 6 Example Rxn No. Enzyme Time (hr) ee % (S-THFA) 24 Aspergillus oryzae lipase 16 100 25 Fongipase 16 100 26 Pseudomonas sp. Lipase 16 100 (immobilized) 27 Pseudomonas sp. Lipase 16 100 28 Candida sp. Lipase 1.5 100 29 Candida antarctica, 1 100 fraction B Lipase 30 Novo IM Lipase 5 100 31 L62 lipase 2.5 100 32 Porcine liver Esterase 0.15 100 - To 200 ml of a 50 mM phosphate buffer (pH 9.0) were added 12% by weight of R, S-THFA butyl ester and 1% by weight ofBacillus licheniformis protease and the resulting reaction was incubated at 30° C. for 10.5 hours with maintenance of pH 9.0. After the hydrolysis, the reaction was analyzed as in Example 1. After the remainder of the reaction was added with 100 ml of ethyl acetate and mixed well, 12 g of S-THFA butyl ester was obtained in the same manner as in Example 14 and identified to be 99.3% in enantiomeric excess.
- In 100 ml of a 50 mM phosphate buffer (pH 7.0), 12 g of the prepared S-THFA butyl ester was hydrolyzed at 30° C. for 5 hours in the presence of 1 g ofCandida antarctica, fraction B lipase with maintenance of pH 7.0. Following the hydrolysis, the reaction results were analyzed as in Example 1. The remainder of the reaction was adjusted to pH 2.0 with HCl, followed by three extractions with 3 volumes of ethyl acetate. After the ethyl acetate extracts were pooled, 6 g of S-THFA was recovered from the pool in the same manner as in Example 14. The compound was found to be 99.3% in enantiomeric excess as measured by chiral GC.
- To 2 liters of a 50 mM phosphate buffer (pH 9.0) were added 40% by weight of R, S-THFA butyl ester and 3% by weight ofBacillus licheniformis protease and the resulting reaction was incubated at 30° C. for 23 hours with maintenance of pH 9.0. After the hydrolysis, the reaction was analyzed as in Example 1. After the remainder of the reaction was added with 1 liter of ethyl acetate and mixed well, 400 g of S-THFA butyl ester was obtained in the same manner as in Example 14 and identified to be 99.3% in enantiomeric excess.
- In 400 ml of a 50 mM phosphate buffer (pH 7.0), 160 g of the prepared S-THFA butyl ester was hydrolyzed at 30° C. for 6 hours in the presence of 8 g ofCandida antarctica, fraction B lipase with maintenance of pH 7.0. Following the hydrolysis, the reaction results were analyzed as in Example 1. The remainder of the reaction was adjusted to pH 2.0 with HCl, followed by three extractions with 3 volumes of ethyl acetate. After the ethyl acetate extracts were pooled, 80 g of S-THFA was recovered from the pool in the same manner as in Example 14. The compound was found to be 99.3% in enantiomeric excess as measured by chiral GC.
- A benzyl ester racemate was prepared in the same manner as in Example 3. To 200 ml of a 50 mM phosphate buffer (pH 9.0) were added 12% by weight of the prepared R, S-THFA butyl ester and 1% by weight ofBacillus licheniformis protease and the resulting reaction was incubated at 20° C. for 4.5 hours with maintenance of pH 9.0. After completion of the hydrolysis, the reaction was analyzed as in Example 1. The remainder of the reaction was added with 100 ml of ethyl acetate and mixed well, after which 16 g of S-THFA butyl ester was obtained in the same manner as in Example 14 and identified to be 99.1% in enantiomeric excess.
- In 20 ml of ethyl acetate was dissolved 55 g of the obtained S-THFA benzyl ester and added 55 mg (1% by weight) of 10% palladium catalyst (Pd/C), followed by stirring the solution at room temperature for 10 min. Hydrogen gas was fed into the reaction little by little to a hydrogen partial pressure of 1.5 Bars at which point stirring was resumed for 10 hours. After removal of the palladium catalyst through filtration, vacuum distillation of the ethyl acetate and produced toluene left 2.5 g of S-THFA. This enantiomeric compound was found to be 99.1% in enantiomeric excess as measured by chiral GC.
- As described hereinafter, α-HCCA and ester thereof can be prepared as enantiomeric compounds with high optical purity at high yields in accordance with the present invention. Additionally, the present invention is economically favorable because such chiral compounds can be produced at low cost.
- The present invention has been described in an illustrative manner, and it is to be understood that the terminology used is intended to be in the nature of description rather than of limitation. Many modifications and variations of the present invention are possible in light of the above teachings. Therefore, it is to be understood that within the scope of the appended claims, the invention may be practiced otherwise than as specifically described.
Claims (6)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR2000-30073 | 2000-06-01 | ||
KR00-30073 | 2000-06-01 | ||
KR10-2000-0030073A KR100378741B1 (en) | 2000-06-01 | 2000-06-01 | Method for preparing R- or S-form α-substituted heterocyclic carboxyl acid and counter enantiomeric form of α-substituted heterocyclic carboxyl acid ester thereto using enzyme |
Publications (2)
Publication Number | Publication Date |
---|---|
US20020006644A1 true US20020006644A1 (en) | 2002-01-17 |
US6440721B2 US6440721B2 (en) | 2002-08-27 |
Family
ID=19671008
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/870,209 Expired - Lifetime US6440721B2 (en) | 2000-06-01 | 2001-05-30 | Method for preparing an R- or S-form of α-substituted heterocyclic carboxylic acid and a counter enantiomeric form of α-substituted heterocyclic carboxylic acid ester thereto using enzyme |
Country Status (7)
Country | Link |
---|---|
US (1) | US6440721B2 (en) |
EP (1) | EP1290209B1 (en) |
JP (1) | JP4843813B2 (en) |
KR (1) | KR100378741B1 (en) |
CA (1) | CA2410441A1 (en) |
DE (1) | DE60143263D1 (en) |
WO (1) | WO2001092554A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109943618A (en) * | 2019-04-10 | 2019-06-28 | 浙江工业大学 | Application of a recombinant lipase in splitting (R,S)-α-ethyl-2-oxo-1-pyrrolidine acetate methyl ester |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100584989B1 (en) * | 2000-08-07 | 2006-05-29 | 에스케이 주식회사 | Racemization method of R-form or S-form 2-tetrahydrofuric acid ester |
KR20030012964A (en) * | 2001-08-06 | 2003-02-14 | 주식회사 제노포커스 | Methods for Preparing Optically Active α-Substituted Heterocycliccarboxylic Acid Ester |
US8076107B2 (en) * | 2007-10-01 | 2011-12-13 | Cargill, Incorporated | Production of monatin stereoisomers |
CN115304564B (en) * | 2022-08-30 | 2024-09-24 | 成都融创亿恒生物医药科技有限公司 | Preparation method of S-tetrahydrofuranic acid |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5037747A (en) * | 1988-01-26 | 1991-08-06 | Hoffmann-La Roche Inc. | Production of benzopyran-2-carboxylic acids and esters by enzymatic hydrolysis |
JPH01216983A (en) * | 1988-02-26 | 1989-08-30 | Hiroyuki Nohira | Method for optical resolution of (+-)-tetrahydrofuran-2-carboxylic acid |
US5057427A (en) * | 1988-04-07 | 1991-10-15 | Sepracor, Inc. | Method for resolution of stereoisomers |
DE3919029A1 (en) * | 1989-06-10 | 1990-12-13 | Hoechst Ag | METHOD FOR ENZYMATICLY CLEAVING 2-ARYLPROPIONIC ACID VINYL ESTER |
IT1247533B (en) * | 1991-04-26 | 1994-12-17 | Mini Ricerca Scient Tecnolog | PROCESS FOR THE SEPARATION OF OPTICAL ISOMERS OF ALPHA-SUBSTITUTE CARBOXYLIC ACIDS |
AT398081B (en) * | 1991-04-29 | 1994-09-26 | Chemie Linz Gmbh | METHOD FOR ENZYMATIC HYDROLYSIS OF A CARBONIC ACID DERIVATIVE |
DE69209357D1 (en) * | 1991-05-09 | 1996-05-02 | Hoffmann La Roche | Substituted carboxylic acid derivatives |
JPH0779712B2 (en) * | 1993-05-17 | 1995-08-30 | 鐘淵化学工業株式会社 | Method for producing optically active indoline-2-carboxylic acid by immobilized enzyme or immobilized microorganism |
JPH08275796A (en) * | 1995-04-07 | 1996-10-22 | Ajinomoto Co Inc | Production of optically active cyclopropane derivative |
JP3603150B2 (en) | 1995-09-06 | 2004-12-22 | 東レ・ファインケミカル株式会社 | Process for producing esters of carboxylic acids |
GB9614856D0 (en) * | 1996-07-15 | 1996-09-04 | Chiroscience Ltd | New resolution method |
BR9714099A (en) * | 1996-12-27 | 2000-03-21 | Smithkline Beecham Plc | Enzymatic revolution of acetic acid-benzodiazepine esters with lipase |
JP3744171B2 (en) * | 1997-01-24 | 2006-02-08 | 住友化学株式会社 | Process for producing optically active N-substituted azetidine-2-carboxylic acid compound |
US5928933A (en) * | 1998-06-26 | 1999-07-27 | E. I. Du Pont De Nemours & Company | Process for the enzymatic resolution of N-(alkoxycarbonyl)-4-ketoproline alkyl esters or N-(alkoxycarbonyl)-4-hydroxyproline alkyl esters using Candida antarctica lipase B |
KR100395310B1 (en) * | 2000-06-01 | 2003-08-21 | 에스케이 주식회사 | Method for optically resolving preparing R- or S-form α-substituted heterocyclic carboxyl acid using enzyme |
KR100368735B1 (en) * | 2000-06-01 | 2003-01-24 | 에스케이 주식회사 | Method for preparing R- or S-form α-substituted heterocyclic carboxyl acid using enzyme |
-
2000
- 2000-06-01 KR KR10-2000-0030073A patent/KR100378741B1/en not_active Expired - Fee Related
-
2001
- 2001-05-25 CA CA002410441A patent/CA2410441A1/en not_active Abandoned
- 2001-05-25 DE DE60143263T patent/DE60143263D1/en not_active Expired - Lifetime
- 2001-05-25 EP EP01934595A patent/EP1290209B1/en not_active Expired - Lifetime
- 2001-05-25 JP JP2002500746A patent/JP4843813B2/en not_active Expired - Fee Related
- 2001-05-25 WO PCT/KR2001/000885 patent/WO2001092554A1/en active Application Filing
- 2001-05-30 US US09/870,209 patent/US6440721B2/en not_active Expired - Lifetime
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109943618A (en) * | 2019-04-10 | 2019-06-28 | 浙江工业大学 | Application of a recombinant lipase in splitting (R,S)-α-ethyl-2-oxo-1-pyrrolidine acetate methyl ester |
Also Published As
Publication number | Publication date |
---|---|
EP1290209A1 (en) | 2003-03-12 |
EP1290209A4 (en) | 2006-05-24 |
US6440721B2 (en) | 2002-08-27 |
KR20010108982A (en) | 2001-12-08 |
CA2410441A1 (en) | 2001-12-06 |
KR100378741B1 (en) | 2003-04-07 |
JP2003534808A (en) | 2003-11-25 |
EP1290209B1 (en) | 2010-10-13 |
WO2001092554A1 (en) | 2001-12-06 |
JP4843813B2 (en) | 2011-12-21 |
DE60143263D1 (en) | 2010-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100657212B1 (en) | Method for preparing optically active ester derivatives and acids thereof from racemic esters | |
US6440721B2 (en) | Method for preparing an R- or S-form of α-substituted heterocyclic carboxylic acid and a counter enantiomeric form of α-substituted heterocyclic carboxylic acid ester thereto using enzyme | |
EP0237983B1 (en) | Process for the biotechnological preparation of l (-)-carnitine chloride | |
US6455302B1 (en) | Method for optically resolving a racemic α-substituted heterocyclic carboxylic acid using enzyme | |
US6121025A (en) | Process for producing optically active 3-quinuclidinol derivatives | |
KR100368735B1 (en) | Method for preparing R- or S-form α-substituted heterocyclic carboxyl acid using enzyme | |
KR100395310B1 (en) | Method for optically resolving preparing R- or S-form α-substituted heterocyclic carboxyl acid using enzyme | |
EP0148272B1 (en) | Process for producing optically active benzyl alcohol compounds | |
CA2145230A1 (en) | Enzymatic resolution of asymmetric alcohols by means of vinyl esters of polybasic carboxylic acids | |
JP2003299495A (en) | Method for producing optically active 3-methylglutaric acid monoester | |
KR100758512B1 (en) | Method for preparing optically active 3-hydroxy-3-phenylpropionic acid and optically active 3-acyloxy-3-phenylpropionic acid by enzymatic method | |
JPH0667320B2 (en) | Method for producing D-pantolactone | |
WO1999004028A1 (en) | PROCESS FOR PREPARING OPTICALLY ACTIVE α-TRIFLUOROMETHYLLACTIC ACID AND ANTIPODE ESTERS THEREOF AND METHOD OF PURIFICATION THEREOF | |
JP3741758B2 (en) | Process for producing optically active glycerol derivatives | |
JP4746019B2 (en) | Optically active β-cyanoisobutyric acid and process for producing the same | |
JP4565672B2 (en) | Optically active β-cyanoisobutyric acid and process for producing the same | |
JP4834208B2 (en) | Method for producing (2S, 3R) -2,3-epoxybutyric acid ester | |
WO2006009338A1 (en) | Process for preparing chiral substituted carboxylic acid | |
KR20040042666A (en) | Method for preparing an optically active (R)-2-amino-1-butanol by enzymatic method | |
JP2002095495A (en) | Method for producing optically active aminoalcohol derivative | |
JPH1180103A (en) | Beta-carbamoylisobutyric acids and their production | |
JP2000350594A (en) | Optical resolution of 4-halogeno-3- alkanoyloxybutyronitrile | |
JP2007166908A (en) | Process for producing optically active 3- (3-hydroxyphenyl) -2-alkoxypropanoic acid or 3- (3-hydroxyphenyl) -2-alkoxypropanoic acid ester | |
JP2006219494A (en) | Optically active 3-n substituted aminoisobutyric acids and their salts and production method thereof | |
JP2005341972A (en) | METHOD FOR PRODUCING OPTICALLY ACTIVE alpha-METHYLALKANE DICARBOXYLIC ACID-omega-MONOESTER AND ITS ANTIPODE DIESTER |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: SK CORPORATION, KOREA, REPUBLIC OF Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:UHM, KI-NAM;LIM, SANG CHUL;LIM, JONG-HO;REEL/FRAME:011860/0359 Effective date: 20010522 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
CC | Certificate of correction | ||
FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
AS | Assignment |
Owner name: SK HOLDINGS CO., LTD., KOREA, REPUBLIC OF Free format text: CHANGE OF NAME;ASSIGNOR:SK CORPORATION;REEL/FRAME:020112/0329 Effective date: 20070703 |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
AS | Assignment |
Owner name: SK BIOPHARMACEUTICALS CO., LTD., KOREA, REPUBLIC O Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SK HOLDINGS CO., LTD.;REEL/FRAME:027006/0600 Effective date: 20110823 |
|
FPAY | Fee payment |
Year of fee payment: 12 |
|
AS | Assignment |
Owner name: SK BIOTEK CO., LTD., KOREA, REPUBLIC OF Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SK BIOPHARMACEUTICALS CO., LTD.;REEL/FRAME:036528/0866 Effective date: 20150611 |